Spinal cord injury (SCI) is
perhaps one of the worst injuries
known to occur. Nearly 5000 years
ago the ancient Egyptians determined
this to be "an ailment not to be
treated". Today approximately 10,000
spinal cord injuries occur each
year. Males are four times as likely
and tend to be in the 16-30 year old
age group. The annual cost to the
nation is estimated to be more than
$6 billion. Nationwide motor vehicle
accidents are the most common cause
and increasing the likelihood of
paralysis are a lack of seat belt
usage and an association with
alcohol intoxication. Celebrities
such as actor Christopher Reeve and
the late Kansas City Chief Derrick
Thomas have heightened public
awareness of SCI casting national
attention on therapies and the
search for a cure.
Rarely in any case is the spinal
cord torn in half. Typically what
occurs is a fracture or dislocation
of the spinal column bruising the
spinal cord located within the
spinal column. This is known as the
primary injury and can only be
reversed with prevention of the
accident. Once injured this sets
forth a cascade of events known as
the secondary injury. It is during
this phase that the spinal cord
begins to swell. The body attempts
to repair and remove the damaged
tissue but in doing so causes
irreversible damage to the spinal
nerves. The end result is scar
tissue in an area once rich with
nerve tissue. In adults the body has
very limited capacity for nerve
regeneration resulting in a loss of
functional neural circuits.
Therefore, therapeutic strategies
after SCI are directed at preventing
or decreasing the secondary injury
and restorative or regenerative
interventions.
Methylprednisolone is the first
drug proven to change the outcome
after SCI. This drug seems to
decrease swelling in the cord and
also preserves the structure of the
nerve tissue preventing the
destruction of nerve cells and axons
(nerve highways). Studies verified
improvement in motor and sensation
function when given within 8 hours
of injury. However, the amount of
motor improvement is quite small.
Most patients are treated for 24–48
hours. Various other drugs have been
studied attempting to halt the
cascade of destruction at various
points of the chain but have not
demonstrated any significant
improvements thus far.
The most promising of therapies
are directed to the regeneration of
nerve tissue at the site of injury.
This can be achieved in two ways: by
stimulation of growth of existing
nerves at the site of injury or by
transplanting normal nerve tissue to
the scarred area. The goal of this
treatment is the bridging of axons
across the injury and the
restoration of ascending and
descending pathways.
Growth factors (neurotrophins)
have been shown to improve motor
function in animals although no
human studies have been done. These
compounds can stimulate nerve growth
as well as the formation of myelin,
which insulates the axons and allows
for impulse transmission. This
effectively allows for
reorganization of the injured area.
Tissue transplantation can
provide for a "cellular bridge"
filling in the injured area and
provides chemical and mechanical
cues for repair. It provides for new
neurons and it can provide a variety
of substances that may help with the
repair process. Not only can blocks
of tissue be used such as is done
with fetal cell transplants but
specific cells such as stem cells,
olfactory ensheathing cells, and
Schwann cells can be isolated and
then transplanted. Fetal cells have
been used for Parkinson’s disease
and in the spinal cord can bridge
damaged axons. A problem with this
technique or any other regeneration
technique is the inability to
control target specific interactions
resulting in the improper crossing
of pathways. Additional concerns
include the ability to be able to
turn off the regrowth phenomenon so
as to not get out of hand like a
cancerous growth. These therapies
still need extensive study before
applications in human studies begin.
Clearly there is hope for cure of
paralysis in the future although no
timetable exists for this in the
foreseeable future. Much more
investigative work is needed in
laboratory and animal studies before
human trials can begin. At this
point in time prevention is still
the best remedy.